Pfizer scheme to churn out ‘variant-specific’ vaccines will lead to more variants, experts warn

Share:

(Children’s Health Defense) – Pfizer CEO Albert Bourla on Tuesday told Fox News the company believes a COVID vaccine-resistant variant will likely one day emerge, but the company has a system in place to turn around a variant-specific jab within 95 days if it does.

“Every time a variant appears in the world, our scientists are getting their hands around it,” Bourla said. “And they are researching to see if this variant can escape the protection of our vaccine.”

Bourla said Pfizer hasn’t identified any variants that could escape the vaccine yet. However, that statement contradicts the findings of numerous studies by the Centers for Disease Control and Prevention (CDC) which show waning immunity against the Delta variant.

Pfizer and the Biden administration cited the CDC studies when calling for a third booster dose for the immunocompromised and general population.

Bourla said Pfizer could produce new versions of its vaccine to combat a variant within three months of its discovery.

“We have built a process that within 95 days from the day we identify a variant as a variant of concern, we will be able to have a vaccine tailor-made against this variant,” Bourla said.

Public health officials have said for months universal vaccination across the U.S. and population abroad would reduce the opportunity for the virus to further mutate and evade vaccines.

CDC Director Dr. Rochelle Walensky said during a July 27 press briefing, the big concern is that the next variant that might emerge — just a few mutations away — could potentially evade vaccines.

The U.K. government’s advisory panel, the Scientific Advisory Group for Emergencies, said higher rates of virus circulation and transmission were creating “more opportunities for new variants to emerge.”

But other experts argue it’s universal vaccination that is creating highly transmissible escape mutants capable of evading vaccines and subjecting the unvaccinated to infection.

​​Dr. Peter McCullough, board certified in internal medicine, cardiovascular diseases and clinical lipidology, said in a recent podcast: “There are clearly sources of information to suggest that once we start vaccination and we get more than 25% of the population vaccinated, we will allow one of the variants that’s in the background to emerge because it’s resistant to the vaccine.”

“That [theory] makes sense,” McCullough said. “Just like an antibiotic, once we get to a certain percentage of coverage with an antibiotic, we’ll allow a resistant bacteria to move forward.”

McCullough explained:

“If we were to go back in time six months ago, we had about 14 strains or more in the United States — all relatively small proportions. We had U.K., Brazilian and there was always some Delta, by the way — it was always in the background. And there was a paper by Niessen and colleagues from Boston and Rochester Minnesota, a great paper — over a million sequenced samples. They looked at vaccination rates all over, and the variant proportions, and they concluded that with more than 25% of the population vaccinated, you’ll encourage a dominant strain to move forward.

“We’ve in a sense created now a super-dominant strain, we’ve encouraged a super-dominant strain,” though McCullough noted science showed the Delta variant is milder.

In an interview on “RFK, Jr. The Defender Podcast,” McCullough cited an Aug. 10 study in The Lancet that showed people who are vaccinated against COVID are more susceptible to the Delta variant.

According to McCullough, the paper’s authors demonstrated widespread vaccine failure and transmission under tightly controlled circumstances in a hospital lockdown in Ho Chi Minh City, Vietnam.

Geert Vanden Bossche is a virologist and vaccinologist who worked with GSK Biologicals, Novartis Vaccines, Solvay Biologicals, Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle and GAVI, The Global Alliance for Vaccines and Immunization in Geneva.

In an Aug. 12 article, Vanden Bossche said universal mass vaccination will prompt dominant propagation of highly infectious, neutralization escape mutants, and naturally acquired — or vaccinal neutralizing antibodies — will no longer offer any protection to immunized individuals, whereas high infectious pressure will continue to suppress the innate immune defense system of the unvaccinated.

“This is to say that every further increase in vaccine coverage rates will further contribute to forcing the virus into resistance to neutralizing, S-specific Abs [antibodies]. Increased viral infectivity, combined with evasion from antiviral immunity, will inevitably result in an additional toll taken on human health and human lives,” Vanden Bossche said.

As far back as March, Vanden Bossche said:

“There can be no doubt that continued mass vaccination campaigns will enable new, more infectious viral variants to become increasingly dominant and ultimately result in a dramatic incline in new cases despite enhanced vaccine coverage rates. There can be no doubt either that this situation will soon lead to complete resistance of circulating variants to the current vaccines.”

Vanden Bossche said a combination of lockdowns and extreme selection pressure on the virus and global mass vaccination might diminish the number of cases, hospitalizations and deaths in the short-term, but ultimately, would induce the creation of more escape mutants.

This will trigger vaccine companies to further refine vaccines that will add to the selection pressure, producing ever more transmissible and potentially deadly variants, he added.